Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Heart bypass patients: does a stronger blood thinner keep grafts working longer?

NCT ID NCT04783701

Disease control Sponsor: University Hospital, Linkoeping Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looks at whether taking two blood thinners (ticagrelor plus aspirin) is better than aspirin alone for keeping bypass grafts open in people who had heart surgery after a heart attack. About 360 participants will be followed for 1 to 3 years, and their grafts will be checked with a special CT scan. The goal is to see if the stronger blood-thinning regimen reduces graft blockages.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
ticagrelor (antiplatelet drug) plus aspirin, compared to aspirin alone
What this could lead to
If it works, this could show that adding ticagrelor to aspirin helps keep bypass grafts open longer after heart surgery, potentially reducing the need for repeat procedures.
What could go wrong
This is a relatively small, early-phase study (360 participants) and results may not apply to all patients. The benefit of dual therapy must be weighed against a higher risk of bleeding.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 360 people

The number the study aims to enrol. It can still change while the study runs.

Started

May 2021

Expected to finish

Mar 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

This study will include patients previously included in the TACSI-trial (Dual antiplatelet therapy with ticagrelor and ASA vs. ASA alone after coronary artery bypass grafting in patients with acute coronary syndrome) . This means patients with age ≥18 years that has undergone for the first time an isolated CABG due to an episode of an acute coronary syndrome (ACS) event within 6 weeks before CABG. The randomized, controlled trial TACSI (ClinicalTrials.gov NCT03560310) offers a unique possibility to address the issue of graft patency based on antiplatelet strategy in patients with acute coronary syndromes.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Previously included in TACSI-trial Exclusion Criteria: * Highly irregular heart rhythm (i.e. atrial fibrillation) * Chronic kidney disease with estimated glomerular filtration rate (eGFR) \<45ml/min/1,73m2 * Body weight \>120 kg * Previous severe allergic reaction (i.e. anaphylactic reaction) to iodine-based contrast agents * Not able to communicate * Not willing to participate

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Acute coronary syndrome are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

acute coronary syndrome coronary restenosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Acute coronary syndrome Coronary bypass stenosis

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    5 sites in 2 countries. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Dep of Vascular and Thoracic Surgery

    ACTIVE_NOT_RECRUITING

    Örebro, Sweden

  • Department of Cardiothoracic Surgery Karolinska University Hospital

    ENROLLING_BY_INVITATION

    Stockholm, Sweden

  • Department of Heart Disease, Haukeland University Hospital

    ENROLLING_BY_INVITATION

    Bergen, Norway

  • Department of Molecular and Clinical Medicine, Wallenberg Laboratory, Institute of Medicine

    ENROLLING_BY_INVITATION

    Gothenburg, Sweden

  • St Olavs University Hospital

    NOT_YET_RECRUITING

    Trondheim, Norway

  • University Hospital Linköping

    RECRUITING

    Linköping, Östergötland County, 58185, Sweden

More trials for these conditions

Other studies related to the condition(s) this trial covers.